@article {A. Saad Zaghloul:2013:2210-3090:65,
title = "Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells",
journal = "Recent Patents on Biomarkers",
parent_itemid = "infobike://ben/rpbm",
publishercode ="ben",
year = "2013",
volume = "3",
number = "1",
publication date ="2013-01-01T00:00:00",
pages = "65-71",
itemtype = "ARTICLE",
issn = "2210-3090",
url = "https://www.ingentaconnect.com/content/ben/rpbm/2013/00000003/00000001/art00006",
keyword = "HuH-7, molecular targeted therapy, Functional Integrity Assay, Gastrointestinal Tumors, luciferase reporter gene, p53, MAPK, Hepatocellular carcinoma, imatinib mesylate",
author = "A. Saad Zaghloul, Mai and H. Abadi, Ashraf and I. Abdelaziz, Ahmed",
abstract = "Hepatocellular Carcinoma remains a major fatal disease that is resistant to most cytotoxic therapeutics owed to the aberrant activation of signalling cascades. Recent patents reveal a new family of drugs that has been studied for molecularly targeting these cascades; multi-kinase inhibitors,
are nowadays considered as novel therapeutic approaches. Therefore in this study, we aimed at investigating the impact of Imatinib mesylate, a tyrosine kinase inhibitor, on Human Hepatoma (HuH-7) cellular behavior and specifically its effect on p53 tumor suppressor gene. HuH-7 cells were transfected
with a reporter vector containing a specific enhancer element that is activated upon binding to intracellular p53; consequently downstream luciferase reporter gene is activated. Cells were treated with Imatinib and we looked for p53 induction upon drug stimulation. Additionally; viability,
metabolism, proliferation and apoptosis were evaluated. Upon Imatinib treatment, p53 expression showed a significant increase represented in increased luminescence. Moreover; a decrease in cellular viability and metabolic activity along with a considerable inhibition of proliferation and a
vast increase in Caspase 9 activity were observed when compared to untreated cells. This study suggests that the effects of Imatinib mesylate might be attributable to enhanced active p53 in HuH-7 cells with consequent reduction in cancer progression properties. The article also summarizes
some recent relevant patents.",
}